598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
Main Authors: | Michael Chisamore, Noelly Madeleine, Austin Rayford, Gro Gausdal, David R Micklem, Magnus Blø, Dina Alzhanova, Josephine Amalia Taverna, Chia-Nung Hung, Rolf A Brekken, Claudia Gorcea-Carson, Cristina Oliva, Nigel McCracken |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)
by: S. Loges, et al.
Published: (2022-06-01) -
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
by: Emmett Schmidt, et al.
Published: (2020-11-01) -
Generation of an iPSC cohort of isogenic iPSC lines (46-XY and 47-XXY) from a non-mosaic Klinefelter Syndrome patient (47-XXY) (KAUSTi008-A, KAUSTi008-B, KAUSTi008-C, KAUSTi008-D, KAUSTi008-E, KAUSTi008-F, KAUSTi008-G)
by: Elisabetta Fiacco, et al.
Published: (2021-01-01) -
NCT:noise-control multi-object tracking
by: Kai Zeng, et al.
Published: (2023-01-01) -
The impact of NCT on women environment Indonesia case
by: Ina R Suparto.
Published: (2008)